Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial

Bailey TS et al. Diabetes Obes Metab. 2016. doi: 10.1111/dom.12736.

Study design:

A phase 4, 26-week, randomized, multicentre, parallel-group, double-blind, double-dummy, active-controlled trial.

Randomization (1:1)
Treatment duration 26 weeks

Inclusion criteria:

  • Inadequately controlled on stable sitagliptin + MET (A1C 7.5–9.5%)

  • BMI ≥20 kg/m2

  • ≥18 years of age

Results:

At 26 weeks, patients who were inadequately controlled on sitagliptin + MET achieved:

Statistically significant A1C reductions on a regimen of Victoza® + MET vs. continuing sitagliptin + MET.5‡

(n=204)

Victoza®
1.8 mg + oral placebo + MET

(n=203)

sitagliptin
100 mg + placebo injection + MET

§ p<0.0001 for Victoza® 1.8 mg + MET + oral placebo vs. sitagliptin 100 mg + MET + placebo injection.

Statistically significant weight reductions on a
regimen of Victoza® + MET vs. continuing sitagliptin +
MET (2° endpoint).5‡

(n=204)

Victoza®
1.8 mg + oral placebo + MET

(n=203)

sitagliptin
100 mg + placebo injection + MET

p<0.0001 for Victoza® 1.8 mg + MET + oral placebo vs. sitagliptin 100 mg + MET + placebo injection.

*Starting dose at 0.6 mg/day with weekly dose escalation up to 1.8 mg/day.

One subject was not exposed to the trial medication.

Baseline values for Victoza® + MET/sitagliptin + MET arm: A1C (%): 8.3/8.2; body weight (kg): 88.9/91.2.

A1C, glycated hemoglobin; BMI, body mass index; MET, metformin.

At 26 weeks, in patients inadequately controlled on sitagliptin + MET:

A statistically significant proportion of patients achieved target A1C <7% on a regimen of
Victoza® + MET at 50.6% vs. 26.9% continuing sitagliptin + MET (2° endpoint).5

“...a robust randomized, double-blind, double-dummy, active-controlled [trial designed] to address the question of whether patients with T2D insufficiently controlled on sitagliptin therapy might obtain improved glycaemic control [with] liraglutide.”1

— Bailey TS et al.

Consider Victoza® for your patients with type 2 diabetes who are
inadequately controlled on sitagliptin (both in combination with metformin).

Ask Med Info

If you have a specific question about Victoza®, please email our Medical Information team using the form below. We will get back to you as soon as possible.



Resources

The latest Victoza® Product Monograph dated June 15, 20171.

The new Victoza® VIP program is a resource for you to use with your patients during consultations, including how-to videos and other resources to get them started.

TRUST in our real-world experience.

#1 GLP-1 receptor agonist dispensed, Canada and worldwide2,3

>1,130,000 patients worldwide have been prescribed Victoza® 3